Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Intralesional Measles Mumps and Rubella vaccine: 0.3ml of MMR vaccine is instilled intralesionally into the largest Molluscum contagiosum lesion at 2 week intervals planned for four sit
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: Clinically diagnosed patients with multiple ( 2 or more) lesions of Molluscum contagiosum with no history of topical or systemic therapy taken for current lesions and are willing for follow up.
Exclusion criteria
Exclusion criteria: 1. Patients with a past history of allergic response to MMR or any other vaccine. 2. Patients with acute febrile illness or bacterial infections. 3. Patients with immunosuppression, HIV infection, Hepatitis B or Hepatitis C infection. 4. Patients with only anogenital lesions. 5. Pregnant or lactating women. 6. Patients having a history of asthma, allergic skin disorders or convulsions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of the lesions based on size, number and photographic comparisonTimepoint: Every 2 weeks for first 8 weeks, then monthly till end of 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| To study side effects of intralesional MMR therapy. To find recurrence rate post treatment with intralesional MMR.Timepoint: Every 2 weeks for first 8 weeks, then monthly till end of 6 months. | — |
Countries
India
Contacts
Public ContactShruthi Pavana Janardhanan
Madras Medical College
Outcome results
None listed